Format

Send to

Choose Destination
Trends Mol Med. 2015 Oct;21(10):609-621. doi: 10.1016/j.molmed.2015.07.006.

Modeling Disease In Vivo With CRISPR/Cas9.

Author information

1
Department of Medicine, Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY 10021, USA. Electronic address: lud2005@med.cornell.edu.

Abstract

The recent advent of CRISPR/Cas9-mediated genome editing has created a wave of excitement across the scientific research community, carrying the promise of simple and effective genomic manipulation of nearly any cell type. CRISPR has quickly become the preferred tool for genetic manipulation, and shows incredible promise as a platform for studying gene function in vivo. I discuss the current application of CRISPR technology to create new in vivo disease models, with a particular focus on how these tools, derived from an adaptive bacterial immune system, are helping us to better model the complexity of human cancer.

KEYWORDS:

CRISPR; Cas9; cancer; in vivo

PMID:
26432018
PMCID:
PMC4592741
DOI:
10.1016/j.molmed.2015.07.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center